Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Expands Immunotherapy Footprint With Anti-PD-1

This article was originally published in The Pink Sheet Daily

Executive Summary

In a Phase I trial reported at ASCO, BMS’ new immunotherapeutic antibody BMS-936558 had impressive results against melanoma, renal cell cancer and non-small cell lung cancer, including the intractable squamous cell variety. The company is already testing it in combination with Yervoy to “move melanoma treatment to new heights.”

You may also be interested in...

MedImmune Pipeline Primed To Produce

MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.

Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point

Bristol-Myers Squibb’s “anti-PD-1,” an antibody that gets between immune system T-cells out to destroy cancer cells and a cancer defense mechanism that would tie them up, caught the fancy of attendees at the American Society of Clinical Oncology annual meeting in Chicago with Phase I data indicating the drug could be safer and more effective than Bristol’s breakthrough immunotherapeutic for melanoma, Yervoy.

BMS’ Andreotti Talks BD Beyond 2015

Oncology, virology and cardiovascular remain top therapeutic priorities in mid-term, but longer term focus at BMS is shifting to oncology, CNS and cardiovascular and metabolic diseases, CEO Lamberto Andreotti tells analysts at Sanford F. Bernstein conference.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts